The Oncology Institute, Inc. $TOI Shares Bought by CenterBook Partners LP

CenterBook Partners LP raised its position in The Oncology Institute, Inc. (NASDAQ:TOI) by 12.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,029,312 shares of the company’s stock after acquiring an additional 324,662 shares during the quarter. CenterBook Partners LP’s holdings in Oncology Institute were worth $10,784,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Pekin Hardy Strauss Inc. purchased a new stake in shares of Oncology Institute during the fourth quarter worth approximately $36,000. R Squared Ltd purchased a new stake in shares of Oncology Institute during the fourth quarter worth approximately $41,000. Prelude Capital Management LLC purchased a new stake in shares of Oncology Institute during the third quarter worth approximately $41,000. BNP Paribas Financial Markets increased its position in shares of Oncology Institute by 141.0% during the third quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock worth $42,000 after purchasing an additional 7,091 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC purchased a new stake in shares of Oncology Institute during the third quarter worth approximately $51,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on TOI. BTIG Research reiterated a “buy” rating and set a $7.00 price target on shares of Oncology Institute in a research report on Monday, March 9th. B. Riley Financial boosted their price target on Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price target on shares of Oncology Institute in a research report on Monday, March 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a research report on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Oncology Institute Price Performance

Shares of NASDAQ:TOI opened at $4.87 on Monday. The business has a fifty day moving average of $3.78 and a two-hundred day moving average of $3.39. The stock has a market cap of $481.35 million, a P/E ratio of -13.16 and a beta of 0.37. The Oncology Institute, Inc. has a 52-week low of $2.02 and a 52-week high of $5.17.

Oncology Institute (NASDAQ:TOI) last issued its earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.05. The company had revenue of $147.44 million during the quarter, compared to analysts’ expectations of $142.10 million. On average, equities analysts anticipate that The Oncology Institute, Inc. will post -0.17 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Mohit Kaushal sold 57,286 shares of the stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $3.50, for a total transaction of $200,501.00. Following the completion of the transaction, the director directly owned 211,016 shares in the company, valued at approximately $738,556. This represents a 21.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett purchased 263,000 shares of the stock in a transaction dated Friday, March 13th. The shares were acquired at an average price of $2.92 per share, with a total value of $767,960.00. Following the completion of the acquisition, the insider owned 10,115,944 shares in the company, valued at approximately $29,538,556.48. This trade represents a 2.67% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have bought 649,485 shares of company stock valued at $2,095,896. Company insiders own 8.50% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.